Goldline Pharmaceutical IPO GMP Day 3 14 May 2026: GMP Surges to Rs 25, Subscription 73.35x on Day 2, Closes Today at 5 PM

May 14, 2026
Posted by: Ankit Jaiswal
Category: IPO

The Goldline Pharmaceutical IPO is on Day 3 and the final day of subscription on 14 May 2026 with the grey market premium (GMP) surging to Rs 25 per share on 14 May, a new high from Rs 16 to Rs 18 seen across Days 1 and 2. At Rs 25 GMP over the Rs 43 upper band, the implied listing price is approximately Rs 68, representing an expected listing gain of 58.14 percent according to IPOWatch data. The Goldline Pharmaceutical IPO closes today at 5 PM and this is the last opportunity to apply.

The massive subscription data from Day 2 has turbo-charged grey market sentiment. As of 13 May at 2:59 PM, the Goldline Pharmaceutical IPO was subscribed 73.35 times overall and 106.13 times in the individual investor (retail) category alone. With Day 3 QIB participation yet to be fully counted, the final subscription figure when the window closes today is expected to cross 100 times or more overall.

Table of Contents

Goldline Pharmaceutical IPO Day 3: Complete Key Details

Exchange: BSE SME
Issue Opens: 12 May 2026
Issue Closes: 14 May 2026 TODAY at 5 PM (LAST DAY to apply)
Allotment Date: 15 May 2026
Credit of Shares: 18 May 2026
Listing Date: 19 May 2026
Price Band: Rs 41 to Rs 43 per share
Face Value: Rs 10 per share
Issue Size: Rs 11.61 crore (100% fresh issue, 25.62 lakh shares + 1.38 lakh market maker reserved)
Lot Size: 3,000 shares (minimum retail application 2 lots = 6,000 shares at Rs 2,58,000)
Category Split: QIB 50%, Retail 35%, NII 15%
GMP on Day 3 (14 May 2026): Rs 25 (58.14% implied listing premium, expected listing price Rs 68)
GMP High: Rs 25 on 14 May (IPOWatch)
GMP Low: Rs 7 on 8 May (IPOWatch)
Day 2 Overall Subscription (13 May, 2:59 PM): 73.35 times
Day 2 Retail Subscription: 106.13 times
PE at Issue Price: 10.48 times (vs industry range 13 to 15 times)
Lead Manager: Cumulative Capital Pvt Ltd
Registrar: Bigshare Services Pvt Ltd
Market Maker: Nirman Share Brokers

Track live Goldline Pharmaceutical IPO subscription on the Check the Univest Screener for live data.

Why Goldline Pharmaceutical IPO GMP Has Surged to Rs 25 on Day 3

73x Subscription on Day 2 Drove the GMP Surge

The Goldline Pharmaceutical IPO GMP jumping from Rs 16 to Rs 18 on Day 2 to Rs 25 on Day 3 is a direct consequence of the 73.35 times overall subscription figure. When an issue is subscribed 73 times on Day 2 with Day 3 QIBs still to participate fully, grey market participants aggressively re-price the GMP upward. The 106.13 times retail subscription confirms that individual investors have strongly backed the Nagpur-based pharma marketing company at the Rs 43 issue price, creating a secondary demand dynamic in the unlisted market.

For reference, a 73x Day 2 subscription places Goldline Pharmaceutical IPO among the most oversubscribed SME issues of 2026. The final Day 3 subscription, which will include the bulk of QIB participation (allocated 50 percent), could push the overall book past 100 times if institutional demand matches retail enthusiasm.

GMP at Rs 25 on 14 May: What This Implies

A GMP of Rs 25 on 14 May against the Rs 43 upper band implies an expected listing price of approximately Rs 68, representing a 58.14 percent gain over the issue price. This is one of the highest GMP-implied listing premiums for any currently active SME IPO and would translate to a gain of approximately Rs 15,000 on the minimum retail application of 6,000 shares at Rs 43, assuming the listing price meets the GMP expectation.

However, GMP is unofficial and volatile. The Goldline Pharmaceutical IPO GMP has ranged from Rs 7 on 8 May to Rs 25 on 14 May, a range of Rs 18. Investors should not treat the Rs 25 GMP as a guaranteed listing price. Market conditions on 19 May, including broader Nifty levels, crude oil prices and overall SME sector sentiment, will ultimately determine the actual listing price.

Tap to Access Best Research Pieces on Univest

Goldline Pharmaceutical: Business, Fundamentals and Risks

Asset-Light Pharma Marketing: The Business Model

Goldline Pharmaceutical Ltd, incorporated in February 2005 and headquartered in Nagpur, is an asset-light pharma marketing company operating under the Goldline brand across five therapeutic segments: Goldline Pharma (42 products covering physicians, orthopaedics, ENT, surgery, gastroenterology, neurology and urology), Goldline Cardinal (54 products for diabetology, endocrinology and cardiology), Goldline Aayushman (18 products for paediatrics), Goldline InLife (22 products for critical care and ICU) and Goldline Wellness (10 products for cancer supportive care).

The company has 15 third-party contract manufacturers and currently sells through 7 to 8 distributors across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar. All manufacturing is outsourced, allowing the company to focus capital on branding, regulatory work and sales force expansion rather than plant and equipment.

Financial Performance

FY25 Revenue: Rs 28.06 crore (up 19% from Rs 23.57 crore in FY24)
FY25 PAT: Rs 2.83 crore (up 56.4% from Rs 1.81 crore in FY24)
ROE: 27.34% (strong for an asset-light SME)
Debt-to-Equity: 1.54 times (moderate)
PE at Issue Price: 10.48 times vs industry average 13 to 15 times
Tax Litigation: Rs 271.23 lakh (direct tax) and Rs 63.70 lakh (indirect tax) in outstanding contingent liabilities

Key Risks in the Goldline Pharmaceutical IPO

Related Party Revenue Dependency: 22.04% of company revenue comes from three promoter-group entities acting as distributors. This is a material conflict of interest risk.
Geographic Concentration: Maharashtra contributes approximately 44% of revenue. A single-state concentration creates earnings vulnerability.
No Manufacturing Facility: Entirely dependent on 15 third-party manufacturers. Any regulatory action, quality failure or capacity shortfall at a key manufacturer could directly disrupt business.
Small Revenue Scale: Rs 28 crore revenue makes this an early-stage growth story. Working capital stress or a single large client issue could disproportionately impact financials.
Market Condition on Listing Day: Listing is on 19 May with Nifty under pressure from crude above $107. Even a 73x subscribed SME could see a muted listing if the broader market is weak.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical IPO allotment status and BSE SME IPO tracking!

Should You Apply for Goldline Pharmaceutical IPO on Day 3

With the Goldline Pharmaceutical IPO subscribed 73.35 times on Day 2 and GMP at Rs 25, allotment probability for retail investors is now governed by a computerised lottery. Every successful retail applicant receives 1 lot (6,000 shares). Applying for more lots does not increase allotment chances. The expected gain per allotted lot at the Rs 25 GMP-implied listing of Rs 68 is approximately Rs 15,000 on a Rs 2,58,000 investment (approximately 5.8 percent effective return on capital blocked).

For today’s Day 3 applicants, the key question is whether the actual listing on 19 May will honour the GMP-implied Rs 68 price. Given the 73x subscription, the post-listing demand supply dynamic should support the stock well above the issue price. However, GMP is not a guarantee. Consult a SEBI-registered advisor and apply only if you are comfortable with the business risks including related party dependency, geographic concentration and the broader weak market environment.

Conclusion

The Goldline Pharmaceutical IPO closes today on 14 May 2026 with GMP surging to Rs 25, implying a 58.14 percent expected listing gain and a listing price of approximately Rs 68 against the Rs 43 issue price. Day 2 subscription of 73.35 times overall and 106.13 times retail confirms exceptional demand. The final Day 3 QIB participation is expected to push the book past 100 times. The listing on 19 May at BSE SME is one of the most anticipated SME debuts of May 2026. Track live allotment status from 15 May on the Bigshare Services registrar website. Consult a SEBI-registered advisor before making any investment decision based on the Goldline Pharmaceutical IPO GMP.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

FAQs on Goldline Pharmaceutical IPO Day 3

What is the Goldline Pharmaceutical IPO GMP on Day 3, 14 May 2026?

Ans. The Goldline Pharmaceutical IPO GMP has surged to Rs 25 on Day 3 (14 May 2026), up from Rs 16 to Rs 18 on Days 1 and 2. This Rs 25 GMP implies an expected listing price of approximately Rs 68 against the upper band of Rs 43, representing a 58.14 percent listing premium. IPOWatch notes the Day 3 GMP of Rs 25 is the highest level in the issue’s grey market history.

How many times was the Goldline Pharmaceutical IPO subscribed on Day 2?

Ans. The Goldline Pharmaceutical IPO was subscribed 73.35 times overall and 106.13 times in the retail individual investor category as of Day 2 (13 May 2026 at 2:59 PM). Final Day 3 data including full QIB participation will only be available after the 5 PM close today.

Is today the last day to apply for Goldline Pharmaceutical IPO?

Ans. Yes, 14 May 2026 is the last day to apply for the Goldline Pharmaceutical IPO. The subscription window closes at 5 PM today. Allotment is on 15 May, shares are credited on 18 May and the stock lists on BSE SME on 19 May 2026.

What are the chances of getting Goldline Pharmaceutical IPO allotment?

Ans. With retail subscription at 106.13 times on Day 2, retail allotment is by computerised lottery at 1 lot (6,000 shares) per successful applicant. Applying for more lots does not increase allotment chances. At 106x retail subscription, approximately 1 in every 106 retail applicants will receive allotment.

How do I check Goldline Pharmaceutical IPO allotment status?

Ans. Goldline Pharmaceutical IPO allotment status will be available from 15 May 2026 on the Bigshare Services Pvt Ltd registrar website. Check using your PAN number, application number or DP ID. You can also check on the BSE website’s IPO allotment page or through your broker app.

IPO GMP Day 3

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.